These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 36208408)

  • 1. Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.
    Shao S; Wang G
    Dermatol Ther (Heidelb); 2022 Dec; 12(12):2627-2635. PubMed ID: 36208408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spesolimab for generalized pustular psoriasis: a review of two key clinical trials supporting initial US regulatory approval.
    Gwillim EC; Nichols AJ
    Front Immunol; 2024; 15():1359481. PubMed ID: 39104539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis.
    Morita A; Choon SE; Bachelez H; Anadkat MJ; Marrakchi S; Zheng M; Tsai TF; Turki H; Hua H; Rajeswari S; Thoma C; Burden AD
    Dermatol Ther (Heidelb); 2023 Jan; 13(1):347-359. PubMed ID: 36333618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial.
    Tsai TF; Zheng M; Ding Y; Song Z; Liu Q; Chen Y; Hu H; Xu J
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3097-3110. PubMed ID: 37840119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study.
    Burden AD; Okubo Y; Zheng M; Thaçi D; van de Kerkhof P; Hu N; Quaresma M; Thoma C; Choon SE
    Exp Dermatol; 2023 Aug; 32(8):1279-1283. PubMed ID: 37140190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare.
    Choon SE; Lebwohl MG; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Rajeswari S; Deng H; Tetzlaff K; Thoma C; Bachelez H
    BMJ Open; 2021 Mar; 11(3):e043666. PubMed ID: 33785490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial of Spesolimab for Generalized Pustular Psoriasis.
    Bachelez H; Choon SE; Marrakchi S; Burden AD; Tsai TF; Morita A; Navarini AA; Zheng M; Xu J; Turki H; Anadkat MJ; Rajeswari S; Hua H; Vulcu SD; Hall D; Tetzlaff K; Thoma C; Lebwohl MG;
    N Engl J Med; 2021 Dec; 385(26):2431-2440. PubMed ID: 34936739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
    Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study.
    Elewski BE; Lebwohl MG; Anadkat MJ; Barker J; Ghoreschi K; Imafuku S; Mrowietz U; Li L; Quaresma M; Thoma C; Bachelez H
    J Am Acad Dermatol; 2023 Jul; 89(1):36-44. PubMed ID: 36870370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: Results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study.
    Morita A; Tsai TF; Yee EYW; Okubo Y; Imafuku S; Zheng M; Li L; Quaresma M; Thoma C; Choon SE
    J Dermatol; 2023 Feb; 50(2):183-194. PubMed ID: 36282833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation.
    Potestio L; Camela E; Cacciapuoti S; Martora F; Guerriero L; Fornaro L; Ruggiero A; Megna M
    Expert Opin Drug Saf; 2023; 22(11):1003-1010. PubMed ID: 37768729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report.
    Wen P; Liu C; Wang T; Jiang X; Wang P; Wang S
    Front Immunol; 2024; 15():1338285. PubMed ID: 38464535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis.
    Baum P; Visvanathan S; Garcet S; Roy J; Schmid R; Bossert S; Lang B; Bachelez H; Bissonnette R; Thoma C; Krueger JG
    J Allergy Clin Immunol; 2022 Apr; 149(4):1402-1412. PubMed ID: 34678325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab.
    Hawkes JE; Visvanathan S; Krueger JG
    Front Immunol; 2023; 14():1292941. PubMed ID: 38077370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature Search.
    Puig L; Fujita H; Thaçi D; Zheng M; Hernandez Daly AC; Leonardi C; Lebwohl MG; Barker J
    Dermatol Ther (Heidelb); 2024 Sep; 14(9):2331-2378. PubMed ID: 39088126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis.
    Burden AD
    Expert Rev Clin Immunol; 2023 May; 19(5):473-481. PubMed ID: 36960829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
    Menter A; Van Voorhees AS; Hsu S
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study.
    Navarini AA; Prinz JC; Morita A; Tsai TF; Viguier MA; Li L; Thoma C; Sivalingam M; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):730-736. PubMed ID: 36527385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spesolimab for the Treatment of Generalized Pustular Psoriasis.
    Bernardo D; Thaçi D; Torres T
    Drugs; 2024 Jan; 84(1):45-58. PubMed ID: 38114719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spesolimab Reduces Inflammation in Generalized Pustular Psoriasis: Molecular Characterization of Flare Treatment in EFFISAYIL 1.
    Farag A; Visvanathan S; Bachelez H; Morita A; Lebwohl MG; Barker JN; Choon SE; Burden AD; Tsai TF; Leparc G; Delic D; Lang B; Thoma C; Krueger JG
    J Invest Dermatol; 2024 Jul; ():. PubMed ID: 39004117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.